Upside, Downside Movers in the Morning
Upside:
-GETY +121% (announces display partnership with OpenAI)
-DFTX +65% (reports positive Phase 3 Emerge topline results for DT120 ODT in MDD; met primary and all key secondary endpoints)
-APGE +47% (confirms to be acquired by AbbVie for $135.11/shr in $10.9B cash deal)
-RGNX +11% (reportedly FDA drops requirement for Regenxbio’s placebo-controlled trial; FDA agrees to reverse rejection of Navsunli gene therapy)
-BWIN +10% (JPMorgan Chase and Co Raised BWIN to Overweight from Neutral, price target: $28)
-FRVO +10% (announces agreement to develop EGS-Twin digital twin platform for Enhanced Geothermal Systems; reports earnings)
-ACA +7.5% (to be acquired by CRH at $150/shr in all-cash deal valued at $8.5B)
-PLBY +7.2% (repurchases 16.6M shares from Fortress at $1.05/share for ~$17.4M)
-MLTX +6.7% (announces Week 52 Results of Sonelokimab from its Phase 3 VELA Program in Hidradenitis Suppurativa)
-VC +5.5% (multiple broker upgrades)
-SMCI +5.3% (hearing upgraded at boutique firm)
-INTC +3.0% (hearing Mizuho raises price target; momentum)
-ACHV +2.9% (receives FDA CRL for cytisinicline NDA; No efficacy or clinical safety deficiencies identified)
Downside:
-BTQ -10% (files to sell at the market C$150M equity offering)
-MPLT -4.9% (ML-004 IRIS Phase 2 misses primary social communication endpoint in ASD)
-SPCX -3.8% (confirms to launch inaugural senior unsecured notes offering)
-AMBQ -2.9% (files to sell 1.8M shares)
Positions: None.
